Indaptus Therapeutics Provides Clinical Update
Provided By GlobeNewswire
Last update: Sep 4, 2025
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases
Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent
Read more at globenewswire.com
